Clinical Trial Results: Positive clinical trial data, especially regarding enobosarm for breast cancer or sabizabulin for COVID-19, typically causes significant stock price increases. Negative or inconclusive results usually lead to price declines.

Regulatory Approvals: FDA approvals for Veru's drugs are major catalysts. Approval leads to commercialization and revenue generation, impacting investor confidence and stock value. Rejections or delays negatively impact the stock.

Market Sentiment: Overall market conditions and investor risk appetite influence VERU's price. A bullish market may boost speculative stocks like Veru, while a bearish market may cause investors to flee to safer assets.

Competition: Competing drugs and therapies in the same therapeutic areas can impact Veru's market share and potential revenue, influencing stock price. New entrants or breakthroughs by competitors may cause concerns.

Financial Performance: Veru's revenue, expenses, profitability, and cash flow all impact investor perception. Strong financial results boost confidence, while losses or high debt can negatively affect the stock.

News and Media Coverage: Positive or negative news articles, analyst ratings, and media coverage can influence investor sentiment and trading activity, affecting the stock price.

Management Decisions: Strategic decisions by Veru's management, such as acquisitions, partnerships, or changes in development strategy, can impact investor confidence and the stock price.

Patent Protection: The strength and duration of Veru's patents on its drugs are crucial for maintaining market exclusivity and profitability, directly impacting the perceived value of the stock.